Mazurier C, Douay L
Établissement français du sang Île-de-France, 94200 Ivry-sur-Seine, France.
Transfus Clin Biol. 2013 May;20(2):90-4. doi: 10.1016/j.tracli.2013.02.020. Epub 2013 Apr 16.
In vitro generation of red blood cells (RBC) makes sense in a context of recurrent shortage. It could be an interesting complementary source for "classic" transfusion products by combining the sufficiency of supply, homemade production of a particular phenotype of interest and reduced risk of infection. The question that arises is how to produce in vitro RBC? Here we retrace the steps that led to the production of functional RBC, from basic knowledge of in vivo erythropoiesis to in vitro generation of RBC from different sources of stem cells. Regarding the adults HSC, the major finding lies in the recent establishment of proof of concept of their transfusion in humans. Because the induced pluripotent stem cells (IPS) can proliferate indefinitely and be selected for a phenotype of interest, they are obviously the best source of stem cells. Proof of concept of generation of RBC from IPS has been made, but still has to be optimized. We also discuss the key points that need to be solved to achieve clinical transfusion application.
在反复出现血液短缺的情况下,体外生成红细胞(RBC)是有意义的。通过结合充足的供应、特定感兴趣表型的自制生产以及降低感染风险,它可能成为“传统”输血产品的一个有趣的补充来源。出现的问题是如何在体外生产红细胞?在这里,我们追溯了从体内红细胞生成的基础知识到从不同干细胞来源体外生成红细胞的过程中,导致功能性红细胞产生的各个步骤。关于成人造血干细胞(HSC),主要发现在于最近在人体中建立了其输血的概念验证。由于诱导多能干细胞(iPS)可以无限增殖并针对感兴趣的表型进行选择,它们显然是最佳的干细胞来源。已经实现了从iPS生成红细胞的概念验证,但仍有待优化。我们还讨论了实现临床输血应用需要解决的关键点。